A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation

Summary

Hepatocellular carcinoma (HCC) represent approximately 70-85% of liver cancer, in which Hepatitis B virus (HBV) is the major etiologic agent accounting for at least 80% of HCC in Asian countries. Overall, transplantation remains the best option however, HCC recurrence rate is high among liver transplant patients. While there are limited treatment measures for HBV-related HCC recurrences, the study hypothesized that LioCyx is capable of lysing target liver cells expressing the HBV cognate antigens and provide clinical benefit to patients with HBV-related HCC.

Timeline

Start

2018-08

Primary completion

2022-08

Completion

2022-08

Outcome

Outcome not reported

Stopped: “Major changes in manufacturing process and investigational product”

Drugs

Indications